Clinical trial
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced…
NCT00310089 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00310089 |
|---|---|
| Title | AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer |
| Official title | A Pilot Study to Evaluate The Effects of Neoadjuvant AZD2171, a VEGF Receptor Tyrosine Kinase Inhibitor With Docetaxel, Doxorubicin, and Cyclophosphamide Chemotherapy in Previously Untreated Locally Advanced Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug, Other, Procedure |
| Interventions | filgrastim, pegfilgrastim, cediranib maleate, cyclophosphamide, docetaxel, doxorubicin hydrochloride, laboratory biomarker analysis, conventional surgery, neoadjuvant therapy |
| Enrollment | 33 |
| Start date | Jan 1, 2006 |
| Completion | Jul 1, 2007 |
| First posted | Apr 3, 2006 |
| Last update posted | Jun 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: